Aquestive therapeutics licenses sympazan® (clobazam) oral film to assertio holdings, inc.

Warren, n.j., oct. 27, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, announced today a transaction to license sympazan® (clobazam) oral film to otter pharmaceuticals, llc, a subsidiary of assertio holdings, inc. (“assertio”) (nasdaq: asrt), a specialty pharmaceutical company offering differentiated products to patients. sympazan (clobazam) oral film is for the adjunctive treatment of seizures associated with lennox‐gastaut syndrome (lgs) in patients aged two years of age or older.
AQST Ratings Summary
AQST Quant Ranking